Sector revisions Genmab A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 06/02/2026 pm IST			5-day change	1st Jan Change
1,958.00 ^DKK	-1.48%		-3.17%	-3.40%

04/02	Goldman Sachs Lowers Price Target for Genmab to 1,793 Danish Kroner (from 1,880), Reiterates Neutral - BN	FW
04/02	Fitch Highlights Genmab's Antibody Oncology Leadership in Final Rating	MT

Add to a list 0 selected To use this feature you must be a member Log in Sign up	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
GENMAB A/S				13
ARGENX SE				15
WUXI APPTEC CO., LTD.				18
INSMED INCORPORATED				20
BIONTECH SE				19
WUXI BIOLOGICS (CAYMAN) INC.				24
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.				17
AKESO, INC.				21
EXELIXIS, INC.				18
SUMMIT THERAPEUTICS INC.				13
MADRIGAL PHARMACEUTICALS, INC.				15
SAMSUNG EPIS HOLDINGS CO., LTD.	-	-	-	1
ARROWHEAD PHARMACEUTICALS, INC.				12
PHARMAESSENTIA CORPORATION				6
VAXCYTE, INC.				9
NUVALENT, INC.				17
CYTOKINETICS, INCORPORATED				18
Average				15
Weighted average by Cap.				16